Multicenter Intervention Program to Optimize the Clinical Management of Community-acquired Pneumonia in Hospitals

NCT ID: NCT02224716

Last Updated: 2015-06-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

968 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-07-31

Study Completion Date

2015-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the impact of a structured package (bundle) in reducing the use of antimicrobials and hospital stay of patients with community-acquired pneumonia (CAP), and no increase in mortality of these patients in different hospitals.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Community Acquired Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Pre-intervention All patients admitted with a diagnosis of CAP

No interventions assigned to this group

Post intervention All patient admitted with a diagnosis of CAP

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of CAP at hospital admission .
* Age: 18 years or more.

Exclusion Criteria

* Patients with nosocomial pneumonia or criteria related to health care.
* Patients with severe immunosuppression (HIV infection with \<200 CD4+ lymphocytes / mm3), neutropenia (\<500 neutrophils / mm3).
* Patient treated with immunosuppressive drugs.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Fundación Pública Andaluza Progreso y Salud

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pilar Retamar Gentil

Role: STUDY_DIRECTOR

Hospital Universitario Virgen Macarena

Juan Enrique Corzo Delgado

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario Virgen de Valme

Cristina Roca Oporto

Role: PRINCIPAL_INVESTIGATOR

Hospitales Universitarios Virgen del Rocío

Montserrat Pérez Pérez

Role: PRINCIPAL_INVESTIGATOR

Hospital de la Línea de la Concepción

Salvador López Cardenas

Role: PRINCIPAL_INVESTIGATOR

Hospital de Jerez de la Frontera

María del Carmen Almodóvar Pulido

Role: PRINCIPAL_INVESTIGATOR

Hospital de Antequera

Fernando Nebrera Navarro

Role: PRINCIPAL_INVESTIGATOR

Hospital de Formentera

Rosario Javier Martínez

Role: PRINCIPAL_INVESTIGATOR

University Hospital Virgen de las Nieves

Francisca Guerrero Sánchez

Role: PRINCIPAL_INVESTIGATOR

Hospital Universitario Puerta del Mar

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Fundación Pública Progreso y Salud

Seville, Sevilla, Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pilar Retamar Gentil

Role: CONTACT

0034 955 04 04 50

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

María del Mar Benjumea Vargas

Role: primary

0034955040450

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FIS-ANT-2014-01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Surviving Pneumonia
NCT03795662 RECRUITING